文献速递其他结缔组织病

系统性硬化症患者皮肤不同分子特征对应的临床表型

Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2023-03-13

这项多中心研究将165例系统性硬化症(SSc)患者和58例健康对照按皮肤基因表达分为Normal-like、Limited、Fibroproliferative和Inflammatory四种固有亚型(IS)。结果显示Inflammatory亚型mRSS更高,Fibroproliferative亚型影像学间质性肺病(ILD)更常见,Scl-70抗体阳性是ILD最强预测因子,IS分类可识别与传统皮肤或自身抗体分类不同的临床表型。

要点

  • Inflammatory固有亚型患者mRSS为22.1±9.9,高于其他固有亚型(P<0.001)。
  • Fibroproliferative固有亚型影像学ILD患病率为91%,高于其他固有亚型(P=0.04)。
  • Scl-70抗体阳性是ILD最强预测因子(P<0.001)。

核心结论

  • 基于皮肤基因表达的固有亚型分类可识别与传统皮肤或自身抗体分类不同的系统性硬化症临床表型。
  • 固有亚型分类可识别影像学ILD更多的Fibroproliferative亚组、mRSS更高的Inflammatory亚组和表型更轻的Normal-like亚组,并可能为现有系统性硬化症分类系统提供额外临床有用信息。

研究设计与样本

  • 多中心研究,纳入223名参与者,包括165例系统性硬化症患者(115例弥漫型皮肤系统性硬化症和50例局限型皮肤系统性硬化症)和58名健康参与者。
  • 使用先前训练的分类器将系统性硬化症患者和健康参与者分为Normal-like、Limited、Fibroproliferative和Inflammatory四种固有亚型。
  • 收集血清自身抗体、肺功能检查、改良Rodnan皮肤厚度评分(mRSS)和高分辨率胸部计算机断层扫描(HRCT)临床数据。
  • 进行统计分析,比较按固有亚型、传统皮肤分类和血清自身抗体分类的患者。

主要发现

  • Inflammatory固有亚型患者mRSS为22.1±9.9,高于其他固有亚型(P<0.001)。
  • Inflammatory固有亚型患者mRSS为22.1±9.9,高于弥漫型皮肤系统性硬化症患者的19.4±9.4(P=0.05)。
  • Inflammatory固有亚型与其他固有亚型的疾病病程相似(中位[四分位距]月数14.9[19.9]对18.4[31.6];P=0.48)。
  • 在多变量建模中,mRSS与RNA聚合酶III(P=0.07)或抗拓扑异构酶I(Scl-70)(P=0.09)无显著关联。
  • 影像学间质性肺病在Fibroproliferative固有亚型中较其他固有亚型更常见(91%;P=0.04),在局限型皮肤系统性硬化症与弥漫型皮肤系统性硬化症之间患病率相似(67%对76%;P=0.73);Scl-70抗体阳性是间质性肺病最强预测因子(P<0.001);所有局限型皮肤系统性硬化症/Fibroproliferative患者均显示影像学间质性肺病。

关键数值与推荐

  • Inflammatory固有亚型mRSS为22.1±9.9,高于其他固有亚型(P<0.001)。
  • Inflammatory固有亚型mRSS为22.1±9.9,高于弥漫型皮肤系统性硬化症患者的19.4±9.4(P=0.05)。
  • 影像学间质性肺病在Fibroproliferative固有亚型中患病率为91%,高于其他固有亚型(P=0.04)。
  • 影像学间质性肺病在局限型皮肤系统性硬化症与弥漫型皮肤系统性硬化症之间患病率相似(67%对76%;P=0.73)。
  • Scl-70抗体阳性是间质性肺病最强预测因子(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) patients are classified according to degree of skin fibrosis (limited and diffuse cutaneous [lc and dc]) and serum autoantibodies. We undertook the present multicenter study to determine whether intrinsic subset (IS) classification based upon skin gene expression yields additional valuable clinical information. METHODS: SSc patients and healthy participants (HPs) were classified into Normal-like, Limited, Fibroproliferative, and Inflammatory ISs using a previously trained classifier. Clinical data were obtained (serum autoantibodies, pulmonary function testing, modified Rodnan skin thickness scores [mRSS], and high-resolution chest computed tomography [HRCT]). Statistical analyses were performed to compare patients classified by IS, traditional cutaneous classification, and serum autoantibodies. RESULTS: A total of 223 participants (165 SSc [115 dcSSc and 50 lcSSc] and 58 HPs) were classified. Inflammatory IS patients had higher mRSS (22.1 ± 9.9; P < 0.001) than other ISs and dcSSc patients (19.4 ± 9.4; P = 0.05) despite similar disease duration (median [interquartile range] months 14.9 [19.9] vs. 18.4 [31.6]; P = 0.48). In multivariable modeling, no significant association between mRSS and RNA polymerase III (P = 0.07) or anti-topoisomerase I (Scl-70) (P = 0.09) was found. Radiographic interstitial lung disease (ILD) was more prevalent in Fibroproliferative IS compared with other ISs (91%; P = 0.04) with similar prevalence between lcSSc and dcSSc (67% vs. 76%; P = 0.73). Positive Scl-70 antibody was the strongest ILD predictor (P < 0.001). Interestingly, all lcSSc/Fibroproliferative patients demonstrated radiographic ILD. CONCLUSIONS: Classification by IS identifies patients with distinct clinical phenotypes versus traditional cutaneous or autoantibody classification. IS classification identifies subgroups of SSc patients with more radiographic ILD (Fibroproliferative), higher mRSS (Inflammatory), and milder phenotype (Normal-like) and may provide additional clinically useful information to current SSc classification systems.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Yang M, Goh V, Lee J, et al. Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin. Arthritis Care Res (Hoboken). 2023. PMID: 35997480. doi:10.1002/acr.24998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。